These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8180585)

  • 1. Immunomodulatory serum components in head and neck cancer.
    Yamanaka N
    Eur J Cancer B Oral Oncol; 1993 Apr; 29B(2):103-6. PubMed ID: 8180585
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical evaluation of serum immunosuppressive acidic protein (IAP) and acid soluble glycoproteins (ASP) in patients with malignant tumors].
    Shibasaki K; Soga K; Toshima M; Aikawa K; Tsuruya T; Itoh T; Takahashi Y; Tsuchimochi M; Mataga I; Tsuchikawa K
    Shigaku; 1989 Aug; 77(2):701-11. PubMed ID: 2489324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive substance in the sera of head and neck cancer patients.
    Yamanaka N; Harabuchi Y; Himi T; Kataura A
    Cancer; 1988 Oct; 62(7):1293-8. PubMed ID: 3416271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of immunosuppressive acidic protein and other immunological parameters in head and neck cancer patients.
    Nakashima T; Tanaka M; Okamura S
    J Laryngol Otol; 1991 Nov; 105(11):939-45. PubMed ID: 1761949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum glycoproteins in head and neck squamous carcinoma: correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy.
    Wolf GT; Chretien PB; Elias EG; Makuch RW; Baskies AM; Spiegel HE; Weiss JF
    Am J Surg; 1979 Oct; 138(4):489-500. PubMed ID: 90464
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum immunosuppressive acidic protein (IAP) in patients with malignant head and neck tumors.
    Yokode Y; Furusaka T; Kida A; Tomita H
    Auris Nasus Larynx; 1985; 12 Suppl 2():S221-5. PubMed ID: 3879742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of glycoproteins as prognosticators in head and neck malignancy.
    Bathi RJ; Nandimath K; Kannan N; Shetty P
    Indian J Dent Res; 2001; 12(2):93-9. PubMed ID: 11665403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum glycoproteins and prognosis in cancer of the head and neck.
    Suarez Nieto C; Cuesta Garcia A; Fernandez Bustillo E; Mendez Colunga JC; Alvarez Marcos C
    Clin Otolaryngol Allied Sci; 1986 Feb; 11(1):41-5. PubMed ID: 3486058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of immunosuppressive factors (IAP-immunosuppressive acidic protein, IS-immunosuppressive substance) in head and neck cancer].
    Saito T; Dake Y; Kakiuti H; Kato Y; Kuki K; Hayashi Y; Yokota M; Kinoshita K; Kuki S; Kimura T
    Nihon Jibiinkoka Gakkai Kaiho; 1989 Apr; 92(4):588-96. PubMed ID: 2769476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head and neck tumor immunology. II. Humoral immunity.
    Schantz SP; Savage HE; Lee NK
    Cancer Treat Res; 1990; 52():243-63. PubMed ID: 1976369
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of serum derived from patients with head and neck cancer on natural killer cell activity.
    Kumazawa H; Hess M
    Oncology; 1991; 48(5):372-6. PubMed ID: 1745484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer.
    Maass JD; Hoffmann-Fazel A; Goeroegh T; Hoffmann M; Meyer JE; Gottschlich S; Rudert H; Maune S
    Anticancer Res; 2000; 20(3B):2241-3. PubMed ID: 10928185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical value of head and neck tumor markers].
    Gascón Vilaplana P
    Med Clin (Barc); 2007 Dec; 129(20):775-6. PubMed ID: 18093479
    [No Abstract]   [Full Text] [Related]  

  • 14. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
    Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
    Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytotoxic activity of peripheral blood lymphocyte in patients with head and neck malignant tumor].
    Ishida H; Fujitani T
    Nihon Jibiinkoka Gakkai Kaiho; 1988 Jul; 91(7):991-1001. PubMed ID: 3183816
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression.
    Pietrowska M; Polańska J; Suwiński R; Wideł M; Rutkowski T; Marczyk M; Domińczyk I; Ponge L; Marczak L; Polański A; Widłak P
    Int J Oncol; 2012 Jan; 40(1):148-56. PubMed ID: 21894432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoembryonic antigen and head and neck cancer.
    Laarman DA; van Kamp GJ; Balm AJ; Braakhuis BJ; Snow GB
    Clin Otolaryngol Allied Sci; 1991 Apr; 16(2):182-6. PubMed ID: 2070537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of C1q-binding macromolecules within the head and neck cancer patient.
    Schantz SP; Savage HE; Brown BW; Young G; Liu FJ; Reger G; Newman RA
    Cancer Res; 1990 Jul; 50(14):4349-54. PubMed ID: 2364389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of circulating immune complexes in malignant tumours of head and neck.
    Das TK; Aziz M; Rattan A; Sherwani R
    J Indian Med Assoc; 1995 Jan; 93(1):3-7. PubMed ID: 7759908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble immune complexes and squamous cell carcinoma-related antigens in patients with head and neck cancer.
    Yamanaka N; Himi T; Harabuchi Y; Hoki K; Kataura A
    Cancer; 1988 Nov; 62(9):1932-8. PubMed ID: 3167806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.